Loading
Relma-cel was the first CAR-T therapy developed and made in China to be approved, for large B-cell lymphoma that has come back after two treatments.
Approved by the NMPA in September 2021 for relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, three months after the Fosun Kite import of axicabtagene ciloleucel became China's first CAR-T approval; relapsed or refractory follicular lymphoma followed in 2022. The pivotal RELIANCE study (59 patients) reported an objective response rate of 75.9% and complete responses in 51.7%, with low rates of severe cytokine release syndrome. JW Therapeutics was formed in 2016 as a joint venture between Juno Therapeutics and WuXi AppTec, and the product is the Chinese sibling of lisocabtagene maraleucel.
Autologous T cells transduced with a CD19-directed CAR (4-1BB co-stimulatory domain) derived from the JCAR017 construct, manufactured in Shanghai by JW Therapeutics. Connects to CD19.
1.Relmacabtagene autoleucel slips into a pocket on CD19.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| China | 2021 | Relapsed or refractory large B-cell lymphoma after two or more lines |
| China | 2022 | Relapsed or refractory follicular lymphoma after two or more lines |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Relmacabtagene autoleucel" OR ABSTRACT:"Relmacabtagene autoleucel" OR TITLE:"Carteyva" OR ABSTRACT:"Carteyva" OR TITLE:"relma-cel" OR ABSTRACT:"relma-cel" OR TITLE:"JWCAR029" OR ABSTRACT:"JWCAR029") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Relmacabtagene autoleucel, not a curated reading list.
Shares WuXi AppTec, JW Therapeutics and the tag china.
Shares WuXi AppTec and the tag china.
Shares CD19, CAR-T cell therapy and the tag china.
Shares CAR-T cell therapy and the tag china.
Shares Follicular lymphoma and the tag china.
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation and the tag china.
Shares CAR-T cell therapy and the tag china.
Shares CAR-T cell therapy and the tag china.